What a lot of folks neglect are N+1-order effects, because those are harder to quantify and fail to reach the predetermined decision some executive or board or shareholder has already made. Is curing patients a bad business model? Sure, for the biotech company it is, but those cured patients are far more likely to go on living longer, healthier lives, and in turn contribute additional value to society - which will impact others in ways that may also create additional value. That doesn't even get into the jobs and value created through the R&D process, testing, manufacturing, logistics of delivery, ongoing monitoring, etc. As long as the value created is more than the cost of the treatment, then it's a net-gain for the economy even if it's a net loss for that singular business.
If all you're judging is the first-order impacts on a single business, you're missing the forest for the trees.
Of course it is, if you charge the right price, just like “building and selling (not leasing out) houses” can be a good business model.
No subscription or 2nd order effects needed.
But every single use case I've read so far could be done with a pretty affordable SaaS product, Zapier, Automator (app on a mac that's existed for over a decade), or something simple you could make yourself.
It also feels like people are automating things that don't really need to be automated at all (do you really need to be reminded to make coffee?)
I fully realize this is probably me being a curmudgeon, however, I have yet to see someone make an actual, practical use case for it. (I would genuinely like to know one, I just haven't seen it)
all the things I do with openclaw are in that ballpark of usefulness/importance.